COMPASS Pathways plc (CMPS) स्टॉक विश्लेषण

कंपनी का अवलोकन

COMPASS Pathways plc operates as a specialized biotechnology entity dedicated to advancing mental health solutions within the United Kingdom and the United States markets. The company's core focus is on developing COMP360, a therapeutic intervention based on psilocybin, which is currently undergoing Phase III clinical trials for treating treatment-resistant depression. This organization functions within the broader Healthcare sector, specifically classified under the Medical Care Facilities industry, where innovation in psychiatric treatments defines its operational scope. With a total market capitalization of $719.39M and an employee base of 156 individuals, the company maintains a mid-cap profile that reflects its significant investment in late-stage clinical development. Although the company reports no annual revenue in the provided data, indicating a heavy reliance on capital allocation for research rather than commercial sales at this stage, the market valuation suggests substantial investor confidence in the potential value of its pipeline assets.

वित्तीय स्वास्थ्य

The company reports a Net Income of $-287,862,016 and an EBITDA of $-175,074,000 for the trailing twelve months, while revenue figures are listed as unavailable, highlighting a typical pre-commercialization burn rate for biotechnology firms. The substantial gap between the reported net loss and the less severe EBITDA loss reveals a significant impact from non-operating expenses, likely including stock-based compensation or one-time costs associated with clinical trial progression. Despite the net loss, the company maintains a Free Cash Flow of $97.14M, which provides a critical buffer for operational flexibility and the ability to fund ongoing research without immediate external capital injection. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a status consistent with entities that have not yet achieved commercial revenue streams to generate traditional profitability indicators. The firm holds $149.61M in cash against $35.03M in debt, creating a robust liquidity position that outweighs its obligations, even though the debt-to-equity ratio is listed as unavailable due to the negative equity base. The Current Ratio stands at 0.77, suggesting that short-term liabilities slightly exceed short-term assets, which requires careful management of cash reserves to meet upcoming obligations. Furthermore, the Return on Equity is -565.3% and the Return on Assets is -51.7%, metrics that reflect the dilutive nature of losses on the balance sheet and the high capital intensity required before the business model transitions to profitability.

मूल्यांकन आकलन

The company exhibits a Forward P/E of -4.67 while the Trailing Twelve Month P/E is listed as N/A, a disparity that indicates the market is valuing the stock based on future expectations rather than current earnings history. The negative forward P/E ratio implies that analysts anticipate earnings will turn positive or that the current valuation is driven entirely by asset value and pipeline potential rather than historical profitability. The Price to Book ratio is recorded at -10.15, which indicates that the market is pricing the company at a significant discount relative to its book value, a common phenomenon for biotech firms with intangible assets not fully captured on the balance sheet. Alternative valuation metrics such as the Price to Sales ratio (N/A) and the EV/EBITDA of -3.46 further illustrate that traditional multiple-based comparisons are not applicable in the current financial state of the enterprise. The stock has traded between a 52-Week High of $8.90 and a 52-Week Low of $2.25, placing the current trading environment within a wide volatility band that reflects the high-risk nature of the asset class. The Beta value of 2.02 signifies that the stock's price volatility is more than twice as high as the broader market, amplifying both potential gains and losses during periods of market fluctuation.

Growth & Income

The company reports N/A for both Revenue Growth (YoY) and Earnings Growth (YoY), as these metrics are not applicable to a biotechnology company that has not yet generated commercial sales from its primary therapeutic product. In the absence of dividend payments, the company does not distribute a Dividend Yield or maintain a Payout Ratio, as the 0.0% payout ratio confirms that all available resources are retained for reinvestment into clinical trials and operational expansion. This growth strategy prioritizes capitalizing on the Phase III trial for COMP360 and advancing the Phase II clinical program over providing income to shareholders. Consequently, the overall growth and income profile is characterized by a focus on long-term asset appreciation and the potential for future commercialization rather than current income generation or dividend yields.